|Title:||Antidiabetic effect and mode of action of cytopiloyne||Authors:||Chang, C.L.-T.
|Issue Date:||2013||Journal Volume:||2013||Source:||Evidence-based Complementary and Alternative Medicine||Abstract:||
Cytopiloyne was identified as a novel polyacetylenic compound. However, its antidiabetic properties are poorly understood. The aim of the present study was to investigate the anti-diabetic effect and mode of action of cytopiloyne on type 2 diabetes (T2D). We first evaluated the therapeutic effect of cytopiloyne on T2D in db/db mice. We found that one dose of cytopiloyne reduced postprandial glucose levels while increasing blood insulin levels. Accordingly, long-term treatment with cytopiloyne reduced postprandial blood glucose levels, increased blood insulin, improved glucose tolerance, suppressed the level of glycosylated hemoglobin A 1c (HbA 1c), and protected pancreatic islets in db/db mice. Next, we studied the anti-diabetic mechanism of action of cytopiloyne. We showed that cytopiloyne failed to decrease blood glucose in streptozocin- (STZ-)treated mice whose β cells were already destroyed. Additionally, cytopiloyne dose dependently increased insulin secretion and expression in β cells. The increase of insulin secretion/expression of cytopiloyne was regulated by protein kinase Cα (PKCα) and its activators, calcium, and diacylglycerol (DAG). Overall, our data suggest that cytopiloyne treats T2D via regulation of insulin production involving the calcium/DAG/PKCα cascade in β cells. These data thus identify the molecular mechanism of action of cytopiloyne and prove its therapeutic potential in T2D. ? 2013 Cicero Lee-Tian Chang et al.
|DOI:||10.1155/2013/685642||SDG/Keyword:||antidiabetic agent; calcium; cytopiloyne; diacylglycerol; glimepiride; glucose; hemoglobin A1c; insulin; protein kinase C alpha; unclassified drug; animal cell; animal experiment; animal model; antidiabetic activity; article; continuous infusion; controlled study; dose response; drug mechanism; female; glucose blood level; glucose tolerance; insulin blood level; insulin release; long term care; male; molecular mechanics; mouse; non insulin dependent diabetes mellitus; nonhuman; pancreas islet beta cell; priority journal; protein expression; single drug dose; streptozocin diabetes; therapy effect
|Appears in Collections:||生命科學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.